113 related articles for article (PubMed ID: 14756545)
1. Analysis of bone alkaline phosphatase as a marker for the diagnosis of osteoporosis in men under androgen ablation.
Morote J; Trilla E; Esquena S; Abascal JM; Segura RM; Catalan R; Encabo G; Reventós J
Int J Biol Markers; 2003; 18(4):290-4. PubMed ID: 14756545
[TBL] [Abstract][Full Text] [Related]
2. Mineral bone disorder and osteoporosis in hemodialysis patients.
Slouma M; Sahli H; Bahlous A; Laadhar L; Smaoui W; Rekik S; Gharsallah I; Sallami M; Moussa FB; Elleuch M; Cheour E
Adv Rheumatol; 2020 Feb; 60(1):15. PubMed ID: 32102689
[TBL] [Abstract][Full Text] [Related]
3. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
Morote J; Lorente JA; Encabo G
Cancer; 1996 Dec; 78(11):2374-8. PubMed ID: 8941009
[TBL] [Abstract][Full Text] [Related]
4. Multiparameter analysis of serum levels of C-telopeptide crosslaps, bone-specific alkaline phosphatase, cathepsin K, osteoprotegerin and receptor activator of nuclear factor κB ligand in the diagnosis of osteoporosis.
Piatek S; Adolf D; Wex T; Halangk W; Klose S; Westphal S; Amthauer H; Winckler S
Maturitas; 2013 Apr; 74(4):363-8. PubMed ID: 23391500
[TBL] [Abstract][Full Text] [Related]
5. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy.
Loddenkemper K; Bohl N; Perka C; Burmester GR; Buttgereit F
Rheumatol Int; 2006 Feb; 26(4):331-6. PubMed ID: 15887044
[TBL] [Abstract][Full Text] [Related]
6. Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer.
Morote J; M'Hammed YI; Martinez E; Esquena S; Lorente JA; Gelabert A
Urology; 2002 Feb; 59(2):277-80. PubMed ID: 11834402
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
Murphy GP; Troychak MJ; Cobb OE; Bowes VA; Kenny RJ; Barren RJ; Kenny GM; Ragde H; Holmes EH; Wolfert RL
Prostate; 1997 Oct; 33(2):141-6. PubMed ID: 9316655
[TBL] [Abstract][Full Text] [Related]
8. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
[TBL] [Abstract][Full Text] [Related]
9. Correlation between bone mineral density and serum trace elements in response to supervised aerobic training in older adults.
Alghadir AH; Gabr SA; Al-Eisa ES; Alghadir MH
Clin Interv Aging; 2016; 11():265-73. PubMed ID: 27013870
[TBL] [Abstract][Full Text] [Related]
10. Clinical Application of the Ratio of Serum Bone Isoform to Total Alkaline Phosphatase in General Practice.
Yokota Y; Nishimura Y; Ando A; Hanayama Y; Hasegawa K; Hagiya H; Ogawa H; Obika M; Ueda K; Otsuka F
Acta Med Okayama; 2020 Dec; 74(6):467-474. PubMed ID: 33361866
[TBL] [Abstract][Full Text] [Related]
11. Higher serum alkaline phosphatase value indicates the need for bone mineral density testing in non-metastatic prostate cancer patients undergoing androgen deprivation therapy.
Hagiwara K; Sakamoto A; Sasaki K; Kanatani A; Kimura M; Kaneko T; Takahashi S; Yamada Y; Nakagawa T
Jpn J Clin Oncol; 2022 Jan; 52(1):73-80. PubMed ID: 34542155
[TBL] [Abstract][Full Text] [Related]
12. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover.
Garnero P; Darte C; Delmas PD
Bone; 1999 Jun; 24(6):603-9. PubMed ID: 10375203
[TBL] [Abstract][Full Text] [Related]
13. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
Lorente JA; Valenzuela H; Morote J; Gelabert A
Eur J Nucl Med; 1999 Jun; 26(6):625-32. PubMed ID: 10369948
[TBL] [Abstract][Full Text] [Related]
14. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
15. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.
Cooper EH; Whelan P; Purves D
Prostate; 1994 Nov; 25(5):236-42. PubMed ID: 7526352
[TBL] [Abstract][Full Text] [Related]
16. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
[TBL] [Abstract][Full Text] [Related]
17. A variation in Bone Alkaline Phosphatase levels that correlates positively with bone loss and normal levels of aminoterminal propeptide of collagen I in girls with anorexia nervosa.
Calero JA; Muñoz MT; Argente J; Traba ML; Méndez-Dávila C; García-Moreno C; de la Piedra C
Clin Chim Acta; 1999 Jul; 285(1-2):121-9. PubMed ID: 10481928
[TBL] [Abstract][Full Text] [Related]
18. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients.
Ureña P; Hruby M; Ferreira A; Ang KS; de Vernejoul MC
J Am Soc Nephrol; 1996 Mar; 7(3):506-12. PubMed ID: 8704118
[TBL] [Abstract][Full Text] [Related]
19. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology.
Kemink SA; Hermus AR; Swinkels LM; Lutterman JA; Smals AG
J Endocrinol Invest; 2000 May; 23(5):295-303. PubMed ID: 10882147
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of bone mineral density and selected metabolic markers of bone in boys with constitutional delay of growth and puberty].
Krupa B
Ann Acad Med Stetin; 2000; 46():165-76. PubMed ID: 11712302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
